A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy (RECOGNIZE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01497652|
Recruitment Status : Completed
First Posted : December 22, 2011
Last Update Posted : December 16, 2015
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease||Drug: Rasagiline/Placebo Drug: Rasagiline||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||March 2015|
Active Comparator: Treatment Group
Treatment group will receive Rasagiline (Azilect) 1mg daily
0.5 mg for two weeks, then 1 mg for 12 weeks.
Other Name: Azilect
Placebo Comparator: Placebo Group
will receive placebo daily
Will receive placebo pills each day for the entire 14 weeks.
Other Name: Sugar pill
- Montreal Cognitive Assessment [ Time Frame: 14 Weeks ]Best value is 30 and Worst Value is 0. Scores for a series of subscales are not combined for a total overall score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01497652
|United States, District of Columbia|
|Georgetown University Hospital|
|Washington, District of Columbia, United States, 20007|
|Principal Investigator:||Fernando L Pagan, MD||Georgetown University|